Ives DV et al. |
Impact of clarithromycin and azithromycin on patterns of treatment and survival among AIDS patients with disseminated Mycobacterium avium complex. |
1995 |
AIDS |
pmid:7755914
|
Fichtenbaum CJ et al. |
Reply to 'Possible bias of ascertainment in assessing chemoprophylaxis for cryptosporidiosis' by Holmberg and Moorman. |
2001 |
AIDS |
pmid:11546956
|
Holmberg SD and Moorman AC |
Possible bias of ascertainment in assessing chemoprophylaxis for cryptosporidiosis. |
2001 |
AIDS |
pmid:11504998
|
Chaisson RE et al. |
Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection. |
1997 |
AIDS |
pmid:9147422
|
MacÃas J et al. |
Rhodococcus or mycobacterium? An example of misdiagnosis in HIV infection. |
1997 |
AIDS |
pmid:9030376
|
Preston SL et al. |
Drug interactions in HIV-positive patients initiated on protease inhibitor therapy. |
1998 |
AIDS |
pmid:9468380
|
Bayoumi AM and Redelmeier DA |
Preventing Mycobacterium avium complex in patients who are using protease inhibitors: a cost-effectiveness analysis. |
1998 |
AIDS |
pmid:9727572
|
Fichtenbaum CJ et al. |
Rifabutin but not clarithromycin prevents cryptosporidiosis in persons with advanced HIV infection. |
2000 |
AIDS |
pmid:11153670
|
|
High-dose clarithromycin should be avoided. |
1996 |
AIDS Alert |
pmid:11363723
|
|
Physician's aggressive preventive therapy differs. |
1995 |
AIDS Alert |
pmid:11362774
|
|
New drug applications sought. |
1995 |
AIDS Alert |
pmid:11362777
|
|
Researchers find new drugs to fight MAC. |
1995 |
AIDS Alert |
pmid:11362925
|
|
Clarithromycin for MAC. |
1995 |
AIDS Patient Care |
pmid:11361361
|
Rosales CM et al. |
AIDS presenting with cutaneous Kaposi's sarcoma and bacillary angiomatosis in the bone marrow mimicking Kaposi's sarcoma. |
2002 |
AIDS Patient Care STDS |
pmid:12542930
|
Mah Ming JB and Gill MJ |
Drug-induced rhabdomyolysis after concomitant use of clarithromycin, atorvastatin, and lopinavir/ritonavir in a patient with HIV. |
2003 |
AIDS Patient Care STDS |
pmid:12816614
|
Monno R et al. |
Chlamydia trachomatis and Mycobacterium tuberculosis lung infection in an HIV-positive homosexual man. |
2001 |
AIDS Patient Care STDS |
pmid:11788074
|
Yangco BG et al. |
Is primary mycobacterium avium complex prophylaxis necessary in patients with CD4 <50 cells/μL who are virologically suppressed on cART? |
2014 |
AIDS Patient Care STDS |
pmid:24833016
|
Desimone JA et al. |
Treatment of Mycobacterium avium complex immune reconstitution disease in HIV-1-infected individuals. |
2003 |
AIDS Patient Care STDS |
pmid:14746655
|
|
NIAID study rules out high-dose clarithromycin for AIDS-related MAC. |
1996 |
AIDS Patient Care STDS |
pmid:11361534
|
|
New data suggest antibiotic clarithromycin is effective in prolonging life of AIDS patients. |
1996 |
AIDS Patient Care STDS |
pmid:11361575
|
|
Clarithromycin and MAC. |
1996 |
AIDS Patient Care STDS |
pmid:11361673
|
|
Different clarithromycin doses affect mortality. |
1997 |
AIDS Patient Care STDS |
pmid:11361754
|
Aboulafia DM |
Thalidomide-based treatment for HIV-associated multiple myeloma: a case report. |
2003 |
AIDS Read |
pmid:14524324
|
Kahlon SS et al. |
Mycobacterium-avium-intracellulare complex immune reconstitution inflammatory syndrome in HIV/AIDS presenting as osteomyelitis. |
2008 |
AIDS Read |
pmid:18975441
|
Chu J et al. |
Drug efficacy by direct and adjusted indirect comparison to placebo: An illustration by Mycobacterium avium complex prophylaxis in HIV. |
2011 |
AIDS Res Ther |
pmid:21388558
|
Smibert OC et al. |
Short Communication: Mycobacterium avium Complex Infection and Immune Reconstitution Inflammatory Syndrome Remain a Challenge in the Era of Effective Antiretroviral Therapy. |
2017 |
AIDS Res. Hum. Retroviruses |
pmid:28791872
|
Kuwayama H et al. |
Rabeprazole-based eradication therapy for Helicobacter pylori: a large-scale study in Japan. |
2007 |
Aliment. Pharmacol. Ther. |
pmid:17439512
|
Wong WM et al. |
Standard treatment for Helicobacter pylori infection is suboptimal in non-ulcer dyspepsia compared with duodenal ulcer in Chinese. |
2005 |
Aliment. Pharmacol. Ther. |
pmid:15644048
|
Gisbert JP et al. |
Systematic review: Rabeprazole-based therapies in Helicobacter pylori eradication. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12641497
|
Wong WM et al. |
Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12622764
|
Fischbach L and Evans EL |
Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. |
2007 |
Aliment. Pharmacol. Ther. |
pmid:17635369
|
Thijs JC et al. |
Short report: clarithromycin, an alternative to metronidazole in the triple therapy of Helicobacter pylori infection. |
1994 |
Aliment. Pharmacol. Ther. |
pmid:8186339
|
Gisbert JP et al. |
7-day rescue therapy with ranitidine bismuth citrate after Helicobacter pylori treatment failure. |
2005 |
Aliment. Pharmacol. Ther. |
pmid:15882246
|
Logan RP et al. |
Eradication of Helicobacter pylori and prevention of recurrence of duodenal ulcer: a randomized, double-blind, multi-centre trial of omeprazole with or without clarithromycin. |
1995 |
Aliment. Pharmacol. Ther. |
pmid:8527618
|
Boixeda D et al. |
Efficacy of quadruple therapy with pantoprazole, bismuth, tetracycline and metronidazole as rescue treatment for Helicobacter pylori infection. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:12182745
|
Bruley Des Varannes S et al. |
There are some benefits for eradicating Helicobacter pylori in patients with non-ulcer dyspepsia. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11472320
|
Nada T et al. |
DNA typing for Helicobacter pylori isolates from eradication-failed patients: comparison of the isolates before and after therapy. |
2004 |
Aliment. Pharmacol. Ther. |
pmid:15298604
|
Adachi K et al. |
Efficacy of ecabet sodium for Helicobacter pylori eradication triple therapy in comparison with a lansoprazole-based regimen. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11472321
|
Kaneko F et al. |
High prevalence rate of Helicobacter pylori resistance to clarithromycin during long-term multiple antibiotic therapy for chronic respiratory disease caused by non-tuberculous mycobacteria. |
2004 |
Aliment. Pharmacol. Ther. |
pmid:15298607
|
Sierra F et al. |
Pilot study: miscellaneous therapy is highly successful for Helicobacter pylori eradication. |
2013 |
Aliment. Pharmacol. Ther. |
pmid:23656465
|
Bardhan KD et al. |
Ranitidine bismuth citrate with clarithromycin alone or with metronidazole for the eradication of Helicobacter pylori. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11472323
|
Masaoka T et al. |
Second-line treatment of Helicobacter pylori infection after dilution agar methods and PCR-RFLP analysis. |
2004 |
Aliment. Pharmacol. Ther. |
pmid:15298608
|
Kondo Y et al. |
Helicobacter pylori eradication decreases blood neutrophil and monocyte counts. |
2004 |
Aliment. Pharmacol. Ther. |
pmid:15298609
|
Gschwantler M et al. |
Famotidine versus omeprazole in combination with clarithromycin and metronidazole for eradication of Helicobacter pylori--a randomized, controlled trial. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10468682
|
Paré P et al. |
Comparison of ranitidine bismuth citrate plus clarithromycin with omeprazole plus clarithromycin for the eradication of Helicobacter pylori. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10468683
|
Sung JJ et al. |
One-week ranitidine bismuth citrate in combinations with metronidazole, amoxycillin and clarithromycin in the treatment of Helicobacter pylori infection: the RBC-MACH study. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10468684
|
Chiba N et al. |
Economic evaluation of Helicobacter pylori eradication in the CADET-Hp randomized controlled trial of H. pylori-positive primary care patients with uninvestigated dyspepsia. |
2004 |
Aliment. Pharmacol. Ther. |
pmid:14984382
|
de Francesco V et al. |
Primary clarithromycin resistance in Italy assessed on Helicobacter pylori DNA sequences by TaqMan real-time polymerase chain reaction. |
2006 |
Aliment. Pharmacol. Ther. |
pmid:16423002
|
Di Mario F et al. |
Bovine lactoferrin for Helicobacter pylori eradication: an open, randomized, multicentre study. |
2006 |
Aliment. Pharmacol. Ther. |
pmid:16611285
|
Madisch A et al. |
Healing of lymphocytic gastritis after Helicobacter pylori eradication therapy--a randomized, double-blind, placebo-controlled multicentre trial. |
2006 |
Aliment. Pharmacol. Ther. |
pmid:16441467
|
Borody TJ et al. |
Efficacy and safety of rifabutin-containing 'rescue therapy' for resistant Helicobacter pylori infection. |
2006 |
Aliment. Pharmacol. Ther. |
pmid:16441468
|
Laine L |
Review article: esomeprazole in the treatment of Helicobacter pylori. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:12047270
|
Molina-Infante J et al. |
Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: the OPTRICON study. |
2015 |
Aliment. Pharmacol. Ther. |
pmid:25776067
|
Sasaki A et al. |
Long-term observation of reflux oesophagitis developing after Helicobacter pylori eradication therapy. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12823156
|
Sung JJ et al. |
One-week use of ranitidine bismuth citrate, amoxycillin and clarithromycin for the treatment of Helicobacter pylori-related duodenal ulcer. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9726384
|
Wong WM et al. |
One-week omeprazole, furazolidone and amoxicillin rescue therapy after failure of Helicobacter pylori eradication with standard triple therapies. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11929398
|
Pazzi P et al. |
Short-term low-dose pantoprazole-based triple therapy for cure of Helicobacter pylori infection in duodenal ulcer patients. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9726385
|
Harris AW et al. |
Incidence of duodenal ulcer healing after 1 week of proton pump inhibitor triple therapy for eradication of Helicobacter pylori. The Lansoprazole Helicobacter Study Group. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9726387
|
Azuma T et al. |
Pharmacokinetics of clarithromycin in Helicobacter pylori eradication therapy in patients with liver cirrhosis. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10807427
|
Talley NJ et al. |
Nizatidine in combination with amoxycillin and clarithromycin in the treatment of Helicobacter pylori infection. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9678811
|
Vakil N et al. |
Duplicate breath testing to confirm eradication of Helicobacter pylori: incremental benefit and cost in 419 patients. |
2008 |
Aliment. Pharmacol. Ther. |
pmid:18774949
|
Shokri-Shirvani J et al. |
Letter: global emergence of Helicobacter pylori antibiotic resistance - unanswered questions. |
2016 |
Aliment. Pharmacol. Ther. |
pmid:27137738
|
Ricciardiello L et al. |
Efficacy and safety of three 7-day Helicobacter pylori eradication regimens containing ranitidine bismuth citrate. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9678812
|
Cammarota G et al. |
One-week therapy for Helicobacter pylori eradication: ranitidine bismuth citrate plus medium-dose clarithromycin and either tinidazole or amoxycillin. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9678813
|
Louw JA et al. |
Two-week course of pantoprazole combined with 1 week of amoxycillin and clarithromycin is effective in Helicobacter pylori eradication and duodenal ulcer healing. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9678814
|
Ahuja V et al. |
Lansoprazole and secnidazole with clarithromycin, amoxycillin or pefloxacin in the eradication of Helicobacter pylori in a developing country. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9678815
|
Park HG et al. |
Randomised clinical trial: a comparative study of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori infection in naïve patients. |
2012 |
Aliment. Pharmacol. Ther. |
pmid:22066530
|
Yousfi MM et al. |
One-week triple therapy with omeprazole, amoxycillin and clarithromycin for treatment of Helicobacter pylori infection. |
1996 |
Aliment. Pharmacol. Ther. |
pmid:8853767
|
Hawkey CJ et al. |
Safety and efficacy of 7-day rabeprazole- and omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori in patients with documented peptic ulcer disease. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12694089
|
Wong BC et al. |
Rabeprazole-based 3-day and 7-day triple therapy vs. omeprazole-based 7-day triple therapy for the treatment of Helicobacter pylori infection. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11736727
|
Kashimura H et al. |
Polaprezinc, a mucosal protective agent, in combination with lansoprazole, amoxycillin and clarithromycin increases the cure rate of Helicobacter pylori infection. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10215732
|
Lee JM et al. |
Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10215733
|
Neville PM et al. |
The optimal antibiotic combination in a 5-day Helicobacter pylori eradication regimen. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10215734
|
Hoffman JS et al. |
Efficacy of a 1-week regimen of ranitidine bismuth citrate in combination with metronidazole and clarithromycin for Helicobacter pylori eradication. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10215735
|
Cammarota G et al. |
Helicobacter pylori eradication using one-week low-dose lansoprazole plus amoxycillin and either clarithromycin or azithromycin. |
1996 |
Aliment. Pharmacol. Ther. |
pmid:8971300
|
Pilotto A et al. |
Cure of Helicobacter pylori infection in the elderly: effects of eradication on gastritis and serological markers. |
1996 |
Aliment. Pharmacol. Ther. |
pmid:8971305
|
Vcev A et al. |
Pantoprazole, amoxycillin and either azithromycin or clarithromycin for eradication of Helicobacter pylori in duodenal ulcer. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10632647
|
Gisbert JP et al. |
Recurrence of Helicobacter pylori infection after several eradication therapies: long-term follow-up of 1000 patients. |
2006 |
Aliment. Pharmacol. Ther. |
pmid:16556172
|
Tam YH et al. |
Seven-day is more effective than 4-day ranitidine bismuth citrate-based triple therapy in eradication of Helicobacter pylori in children: a prospective randomized study. |
2006 |
Aliment. Pharmacol. Ther. |
pmid:16803605
|
Sengupta S et al. |
Effect of oral clarithromycin on gall-bladder motility in normal subjects and those with gall-stones. |
2006 |
Aliment. Pharmacol. Ther. |
pmid:16803607
|
Laine L et al. |
A United States multicentre trial of dual and proton pump inhibitor-based triple therapies for Helicobacter pylori. |
1997 |
Aliment. Pharmacol. Ther. |
pmid:9354200
|
Rinaldi V et al. |
The management of failed dual or triple therapy for Helicobacter pylori eradication. |
1997 |
Aliment. Pharmacol. Ther. |
pmid:9354202
|
Breuer T et al. |
Clarithromycin, amoxycillin and H2-receptor antagonist therapy for Helicobacter pylori peptic ulcer disease in Korea. |
1997 |
Aliment. Pharmacol. Ther. |
pmid:9354204
|
Wurzer H et al. |
Short-course therapy with amoxycillin-clarithromycin triple therapy for 10 days (ACT-10) eradicates Helicobacter pylori and heals duodenal ulcer. ACT-10 Study Group. |
1997 |
Aliment. Pharmacol. Ther. |
pmid:9354205
|
Harris A |
H. pylori eradication by LAC. |
1997 |
Aliment. Pharmacol. Ther. |
pmid:9354216
|
Jung YS et al. |
Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication. |
2017 |
Aliment. Pharmacol. Ther. |
pmid:28497487
|
De Francesco V et al. |
Sequential treatment for Helicobacter pylori does not share the risk factors of triple therapy failure. |
2004 |
Aliment. Pharmacol. Ther. |
pmid:14871280
|
Koivisto TT et al. |
First-line eradication therapy for Helicobacter pylori in primary health care based on antibiotic resistance: results of three eradication regimens. |
2005 |
Aliment. Pharmacol. Ther. |
pmid:15771764
|
Peterson WL et al. |
Ranitidine bismuth citrate plus clarithromycin is effective for healing duodenal ulcers, eradicating H. pylori and reducing ulcer recurrence. RBC H. pylori Study Group. |
1996 |
Aliment. Pharmacol. Ther. |
pmid:8791947
|
Delchier JC et al. |
Omeprazole-amoxycillin versus omeprazole-amoxycillin-clarithromycin in the eradication of Helicobacter pylori. |
1996 |
Aliment. Pharmacol. Ther. |
pmid:8791948
|
Jaup BH and Norrby A |
Comparison of two low-dose one-week triple therapy regimens with and without metronidazole for cure of H. pylori infection. |
1996 |
Aliment. Pharmacol. Ther. |
pmid:8791950
|
Weldon MJ et al. |
A seven-day Helicobacter pylori treatment regimen using clarithromycin, omeprazole and tripotassium dicitrato bismuthate. |
1996 |
Aliment. Pharmacol. Ther. |
pmid:8791951
|
Tursi A et al. |
Low-dose omeprazole plus clarithromycin and either tinidazole or amoxycillin for Helicobacter pylori infection. |
1996 |
Aliment. Pharmacol. Ther. |
pmid:8791952
|
Gisbert JP et al. |
Fourth-line rescue therapy with rifabutin in patients with three Helicobacter pylori eradication failures. |
2012 |
Aliment. Pharmacol. Ther. |
pmid:22372560
|
Harris AW et al. |
Lansoprazole, clarithromycin and metronidazole for seven days in Helicobacter pylori infection. |
1996 |
Aliment. Pharmacol. Ther. |
pmid:8971302
|
Moshkowitz M et al. |
One week triple therapy with omeprazole, clarithromycin and tinidazole for Helicobacter pylori: differing efficacy in previously treated and untreated patients. |
1996 |
Aliment. Pharmacol. Ther. |
pmid:8971304
|
Wang WH et al. |
High prevalence of Helicobacter pylori infection with dual resistance to metronidazole and clarithromycin in Hong Kong. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10886046
|
Laine L et al. |
Randomized comparison of differing periods of twice-a-day triple therapy for the eradication of Helicobacter pylori. |
1996 |
Aliment. Pharmacol. Ther. |
pmid:8971306
|
Graham DY et al. |
Meta-analysis: proton pump inhibitor or H2-receptor antagonist for Helicobacter pylori eradication. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12755836
|
McNulty CA et al. |
Is Helicobacter pylori antibiotic resistance surveillance needed and how can it be delivered? |
2012 |
Aliment. Pharmacol. Ther. |
pmid:22469191
|